Profile data is unavailable for this security.
About the company
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
- Revenue in USD (TTM)302.00k
- Net income in USD-257.08m
- Incorporated2010
- Employees96.00
- LocationViridian Therapeutics Inc221 CRESCENT STREET, SUITE 103AWALTHAM 02453United StatesUSA
- Phone+1 (617) 272-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.viridiantherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | 0.00 | -214.90m | 1.39bn | 60.00 | -- | 8.09 | -- | -- | -7.44 | -7.44 | 0.00 | 6.37 | 0.00 | -- | -- | 0.00 | -68.40 | -101.87 | -81.72 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 36.90m | -166.28m | 1.40bn | 284.00 | -- | 1.68 | -- | 37.91 | -3.28 | -3.28 | 0.7163 | 12.04 | 0.0451 | -- | 0.9806 | 129,922.50 | -20.33 | -29.45 | -22.03 | -32.98 | -- | -- | -450.64 | -571.36 | -- | -- | 0.0002 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Intellia Therapeutics Inc | 43.09m | -522.28m | 1.40bn | 526.00 | -- | 1.46 | -- | 32.53 | -5.45 | -5.45 | 0.4509 | 9.46 | 0.0357 | -- | 5.62 | 81,912.55 | -43.22 | -31.34 | -47.07 | -34.53 | -- | -- | -1,212.19 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Cassava Sciences Inc | 0.00 | -17.66m | 1.54bn | 29.00 | -- | 9.26 | -- | -- | -0.3772 | -0.3772 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -8.91 | -30.74 | -10.98 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -293.70m | 1.55bn | 108.00 | -- | 4.85 | -- | -- | -1.77 | -1.77 | 0.00 | 2.00 | 0.00 | -- | -- | 0.00 | -65.46 | -- | -70.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 412.58m | -123.82m | 1.55bn | 536.00 | -- | -- | -- | 3.76 | -0.6073 | -0.6073 | 2.01 | -2.26 | 0.8136 | 0.4297 | 6.54 | 769,736.90 | -24.42 | -47.95 | -32.17 | -64.89 | 98.06 | 97.06 | -30.01 | -114.94 | 2.73 | -0.488 | 2.29 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Viridian Therapeutics Inc | 302.00k | -257.08m | 1.55bn | 96.00 | -- | 3.00 | -- | 5,146.21 | -4.31 | -4.31 | 0.005 | 8.94 | 0.0006 | -- | 5.21 | 3,212.77 | -46.71 | -55.59 | -49.63 | -60.32 | -- | -- | -85,127.15 | -5,678.12 | -- | -- | 0.0282 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.57bn | 380.00 | -- | -- | -- | 7.69 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Nurix Therapeutics Inc | 56.42m | -176.98m | 1.58bn | 284.00 | -- | 3.98 | -- | 28.08 | -2.91 | -2.91 | 0.9222 | 5.62 | 0.1373 | -- | -- | 198,676.10 | -43.07 | -33.01 | -52.51 | -39.66 | -- | -- | -313.65 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Dynavax Technologies Corp | 260.81m | 20.48m | 1.62bn | 408.00 | 101.25 | 2.38 | 64.90 | 6.23 | 0.1221 | 0.1221 | 1.83 | 5.19 | 0.2563 | 0.80 | 4.36 | 639,242.60 | 2.01 | 4.16 | 2.14 | 5.71 | 82.85 | 64.83 | 7.85 | 9.19 | 12.34 | -- | 0.247 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 1.65bn | 500.00 | -- | 3.13 | -- | 25.29 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Xencor Inc | 85.16m | -198.24m | 1.69bn | 280.00 | -- | 2.33 | -- | 19.80 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -110.55m | 1.72bn | 148.00 | -- | 1.92 | -- | -- | -2.21 | -2.21 | 0.00 | 15.66 | 0.00 | -- | -- | 0.00 | -19.23 | -- | -20.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.73bn | 445.00 | -- | 2.94 | -- | 10.71 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Data as of Nov 22 2024. Currency figures normalised to Viridian Therapeutics Inc's reporting currency: US Dollar USD
50.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 9.76m | 12.78% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.33m | 5.67% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.27m | 5.59% |
| Deep Track Capital LPas of 30 Sep 2024 | 3.75m | 4.91% |
| Fairmount Funds Management LLCas of 30 Sep 2024 | 3.45m | 4.51% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2024 | 2.90m | 3.79% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 2.81m | 3.68% |
| Commodore Capital LPas of 30 Sep 2024 | 2.55m | 3.34% |
| Kynam Capital Management LPas of 30 Sep 2024 | 2.51m | 3.29% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.38m | 3.12% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
